Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma

Sponsor
Sun Yat-sen University
Study ID
NCT06323382
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Hepatocellular Carcinoma
  • Anti-PD1/PDL1 Antibody
  • Bevacizumab

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Locoregional therapy — PROCEDURE
    TACE procedure The decision to utilize transarterial artery chemoembolization (TACE) was performed through the tumor-feeding artery. The embolization emulsion was a mixture of Epirubicin 30-60 mg, Lobaplatin 30-50 mg, and Lipiodol 10-30 ml, and it was infused into tumor-feeding arteries via a 2.7/2.8 Fr micro-catheter. HAIC procedure Hepatic arterial infusion chemotherapy (HAIC) procedure was performed with FOLFOX regimen: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2.
  • Bevacizumab — DRUG
    15mg/kg or 7.5mg/kg intravenously every 3 weeks
  • Atezolizumab — DRUG
    1200mg intravenously every 3 weeks
  • Tislelizumab — DRUG
    200mg intravenously every 3 weeks
  • Toripalimab — DRUG
    220mg intravenously every 3 weeks
  • Sintilimab — DRUG
    200mg intravenously every 3 weeks
  • Camrelizumab — DRUG
    200mg intravenously every 3 weeks

Study Details

Atezolizumab + Bevacizumab was superior to sorafenib in overall survival in advanced hepatocellular carcinoma. The programmed cell death protein-1 (PD1) and PDL1 inhibitor, was effective and tolerable in patients with advanced hepatocellular carcinoma. We aimed to describe the efficacy and safety of locoregional therapy combined with Bevacizumab and PD1/L1 inhibitor in patients with advanced hepatocellular carcinoma who can not receive radical therapy.

Key Dates

Start date
Jan 1, 2021
Status verified
Aug 2025
Primary completion
Dec 30, 2025
Completion
Dec 30, 2025

Study Design

Enrollment
240 participants (estimated)

Primary Outcome Measure

Progression-Free-Survival (PFS) [ Time Frame: 12 months ]

Central Contacts

Related Studies